Data Limitations Continue To Plague Northera As The NOH Therapy Goes To Its Second Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask the Cardiovascular and Renal Drugs Advisory Committee Jan. 14 whether there is a population that showed a better than mean effect for the primary endpoint of dizziness.
You may also be interested in...
Chelsea’s Northera Plan: Expand Ongoing Study While Assuring Integrity Of Older Data
Chelsea said it will address FDA’s “complete response” letter by modifying and enlarging an ongoing droxidopa clinical trial and submitting all patient source documentation from an ex-U.S. study site in the completed pivotal trial that the agency has called into question.
Northera Ongoing Trial May Satisfy FDA Request For More Efficacy Data, Chelsea Says
In a “complete response” letter to Chelsea for use of droxidopa in treating neurogenic orthostatic hypotension, FDA requests data from an additional trial showing efficacy and durability of effect. Chelsea believes ongoing Study 306, which has had its own efficacy challenges, could fill the bill and enable an NDA resubmission as early as the first quarter of 2013.
FDA Panel Will Weigh Northera’s Short-Term Benefit Vs. Lack Of Durable Effect, Safety Concerns
At its Feb. 23 review of Chelsea Therapeutics’ investigational orthostatic hypotension drug droxidopa, FDA’s Cardiovascular and Renal Drugs Advisory Committee will be asked to discuss sufficiency of the short-term efficacy data, clinical meaningfulness of the effect size and safety issues, including Japanese post-marketing reports of neuroleptic malignant syndrome.